View Older Stories

Feb 23, 2026 12:17PM Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen

Feb 23, 2026 08:04AM Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c

Feb 2, 2026 09:00AM RBC Capital on Axsome Therapeutics (AXSM): 'Still See Upside On ADA Approval And Launch'

Jan 20, 2026 06:39AM Axsome Therapeutics (AXSM) PT Raised to $260 at H.C. Wainwright

Jan 16, 2026 08:30AM Piper Sandler on Axsome Therapeutics (AXSM): 'Raising Stock PT And Remaining Bullish'

Jan 14, 2026 06:56AM Axsome Therapeutics (AXSM) Reiterated at Overweight by Cantor Fitzgerald

Jan 13, 2026 04:52AM Axsome Therapeutics (AXSM) PT Raised to $209 at Baird

Jan 12, 2026 07:08AM Axsome Therapeutics reports preliminary 2025 revenue of $638.5 million

Jan 8, 2026 03:37AM Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight

Jan 5, 2026 07:08AM Needham Names MindMed (MNMD) New Top Pick for 2026, Adds to Conviction List

Jan 5, 2026 06:40AM Axsome Therapeutics (AXSM) PT Raised to $200 at H.C. Wainwright

Jan 2, 2026 09:37AM Axsome Therapeutics (AXSM) PT Raised to $230 at B.Riley

Jan 2, 2026 08:53AM Truist Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Jan 2, 2026 06:23AM Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Dec 31, 2025 01:54PM Baird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'

Dec 31, 2025 01:20PM Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'

Dec 31, 2025 01:19PM Axsome Therapeutics (AXSM) PT Raised to $217 at Mizuho

Dec 31, 2025 12:42PM Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer

Dec 31, 2025 12:19PM Morgan Stanley on Axsome Therapeutics (AXSM)

Dec 31, 2025 08:27AM Axsome Therapeutics (AXSM) PT Raised to $169 at Needham

Dec 31, 2025 08:25AM Truist on Axsome Therapeutics (AXSM): 'We fully expect ADA to be a significantly larger opportunity for AXS-05'

Dec 31, 2025 08:24AM TD Cowen on Axsome Therapeutics (AXSM): 'the sNDA acceptance should be well received by investors'

Dec 31, 2025 06:55AM Axsome receives FDA feedback supporting AXS-12 narcolepsy drug filing

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Nov 6, 2025 07:02AM Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca

Nov 6, 2025 07:01AM Axsome acquires Avenue's subsidiary for epilepsy drug development

Nov 3, 2025 04:51PM Axsome Therapeutics (AXSM) files mixed shelf

Nov 3, 2025 02:39PM Axsome Therapeutics (AXSM) PT Raised to $205 at Guggenheim

Nov 3, 2025 07:11AM Axsome Therapeutics (AXSM) Misses Q3 EPS by 10c

Oct 1, 2025 02:51AM B.Riley Starts Axsome Therapeutics (AXSM) at Buy

Sep 17, 2025 07:32AM Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

Sep 16, 2025 07:19AM Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

Sep 10, 2025 09:16AM RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'

Sep 3, 2025 02:41AM Wells Fargo Assumes Axsome Therapeutics (AXSM) at Overweight

Aug 22, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Aug 21, 2025 06:16AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

Aug 20, 2025 09:36AM Axsome Therapeutics (AXSM) Stock Has 45% Upside, per RBC Capital

Aug 4, 2025 07:34AM Axsome Therapeutics (AXSM) Tops Q2 EPS by 9c

Jul 22, 2025 07:28AM Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

Jul 22, 2025 06:38AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

Jul 18, 2025 09:58AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

Jul 7, 2025 07:02AM Axsome to host brain health R&D event on July 21 in New York

Jul 3, 2025 06:39AM Morgan Stanley Assumes Axsome Therapeutics (AXSM) at Overweight

Jun 10, 2025 09:24AM Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

Jun 10, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Jun 9, 2025 11:54AM Axsome Therapeutics (AXSM) PT Lowered to $183 at Oppenheimer

Jun 9, 2025 07:02AM Axsome Therapeutics (AXSM) Provides Update on the New Drug Application for AXS-14

Jun 3, 2025 08:14AM Oppenheimer Starts Axsome Therapeutics (AXSM) at Outperform

Jun 2, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

May 27, 2025 07:01AM Axsome Therapeutics (AXSM) Settles SUNOSI Patent Litigation with Hetero Labs

View Older Stories